Lunsumio (mosunetuzumab-axgb) / Roche 
Welcome,         Profile    Billing    Logout  
 5 Diseases   9 Trials   9 Trials   228 News 


«123456789101112»
  • ||||||||||  Polivy (polatuzumab vedotin-piiq) / Roche, Lunsumio (mosunetuzumab-axgb) / Roche
    Enrollment open:  Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma (clinicaltrials.gov) -  Oct 28, 2022   
    P2,  N=34, Recruiting, 
    Trial completion date: Oct 2022 --> Nov 2023 Not yet recruiting --> Recruiting
  • ||||||||||  Journal:  Current status and future prospects of diffuse large B-cell lymphoma treatment (Pubmed Central) -  Oct 13, 2022   
    For non-germinal center B-cell type DLBCL, R-CHOP combined with acalabrutinib is being evaluated. This review summarizes the current standard of care for DLBCL and outlines the recently introduced therapeutic agents or those that are under development in Japan.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen, Lunsumio (mosunetuzumab) / Roche, Biogen
    EVOLVETM: a novel costimulatory T cell engager platform engineered for the treatment of immune suppressive tumors (Hall C) -  Oct 6, 2022 - Abstract #SITC2022SITC_1368;    
    We also demonstrate the modular nature of the EVOLVE platform across diverse tumor antigens including B7H4 (VTCN1), the B cell lymphoma antigen CD20 and a novel squamous tumor antigen ULBP2. Conclusions Our data highlight the broad applications of the EVOLVE platform to improve CD8 T cell-mediated anti-tumor immunity and suggest its potential as an emerging, first-in-category immunotherapeutic strategy to address unmet medical needs in oncology.
  • ||||||||||  Bispecifi c Antibodies for Aggressive B-Cell Lymphoma () -  Sep 22, 2022 - Abstract #SOHO2022SOHO_390;    
    P1, P1/2,
    NCT03533283 and or mosunetuzumab, NCT03677154); and lenalidomide or the CElMoDs (NCT05169515, NCT05335018, NCT02568553)...Data from arm 1 of this study using fi rst-line epcoritamab+R-CHOP for high-risk DLBCL has demonstrated an overall response rate of 96%.2 A cohort of transplant-eligible R/R DLBCL patients who received salvage epcoritamab+R-DHAX/C with subsequent ASCT or epcoritamab monotherapy demonstrated OR and CR rates of 82.6% and 60.9%...Conclusion Clinical data indicate that BsAbs will earn a place in regular treatment of relapse aggressive lymphoma. There is broad development potential in earlier lines of therapy and as a salvage following CAR-T cell therapy.
  • ||||||||||  Lunsumio (mosunetuzumab) / Roche, Biogen
    Review, Journal:  Mosunetuzumab: First Approval. (Pubmed Central) -  Aug 27, 2022   
    Mosunetuzumab was recently conditionally approved in the EU for the treatment of relapsed or refractory follicular lymphoma in adults who have received at least two prior systemic therapies. This article summarizes the milestones in the development of mosunetuzumab leading to this first approval for relapsed or refractory follicular lymphoma.
  • ||||||||||  Review, Journal:  Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era. (Pubmed Central) -  Aug 13, 2022   
    R-CHOP is the standard first line therapy and cures more than 60% of patients...The results of different phase 1 trials with BsAbs, including mosunetuzumab, glofitamab, epcoritamab and odeonextamab, have been recently published...Moreover, these BsAbs have demonstrated very promising efficacy in B-cell lymphomas, including in aggressive lymphomas. New trials are currently ongoing to confirm BsAbs efficacy and tolerability, as well as to explore its efficacy in different lines of therapy or in combination with other drugs.
  • ||||||||||  Polivy (polatuzumab vedotin-piiq) / Roche, Lunsumio (mosunetuzumab-axgb) / Roche
    Trial completion date, Trial initiation date, Trial primary completion date, CAR T-Cell Therapy:  CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). (clinicaltrials.gov) -  Aug 4, 2022   
    P2,  N=40, Not yet recruiting, 
    New trials are currently ongoing to confirm BsAbs efficacy and tolerability, as well as to explore its efficacy in different lines of therapy or in combination with other drugs. Trial completion date: Jan 2027 --> Apr 2027 | Initiation date: Jul 2022 --> Oct 2022 | Trial primary completion date: Jan 2025 --> Apr 2025
  • ||||||||||  Brukinsa (zanubrutinib) / BeiGene, Lunsumio (mosunetuzumab-axgb) / Roche
    Trial completion date, Trial primary completion date:  A Study of Mosunetuzumab in People With Follicular Lymphoma (clinicaltrials.gov) -  Jun 22, 2022   
    P2,  N=53, Recruiting, 
    Trial completion date: Mar 2023 --> Nov 2023 | Trial primary completion date: Mar 2023 --> Nov 2023 Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
  • ||||||||||  Journal:  Immunotherapy in indolent Non-Hodgkin's Lymphoma. (Pubmed Central) -  Jun 8, 2022   
    Other agents include MAB targeting T-Cells like mogamulizumab, Denileukin Diftitox and BiTEs or bispecific T cell engagers like Mosunetuzumab, Glofitamab, and Epcoritamab...Another important aspect in immunotherapy is the half-lives of the medication which is an important factor that can influence the evaluation of the response. The MAB treatment showed important benefit in the treatment of iNHL and it continuously shows how rapidly it can develop to provide optimum care and benefit to patients with iNHL.